T he intensive care unit (ICU) is an extremely stressful environment where anxiety is prevalent, pain frequent, rest difficult, and sleep often impossible. Relief of pain and anxiety is often neglected while efforts focus on immediate life-threatening concerns. A growing awareness of ICU imposed stress and the increasing popularity of some modes of mechanical ventilation such as extended ratio ventilation have highlighted the need for effective sedation, analgesia, and occasionally, paralysis.
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The goal of therapy is to provide adequate analgesia, sedation, and anxiolysis without causing adverse autonomic or cardiopulmonary consequences. Above all, sedation and paralysis must be used for the comfort and well being of the patientâ€"not that of the staff. Akin to the operating room setting, a balanced, multidrug approach is usually the best way to maximize patient comfort and minimize side effects.
On the rare occasions when it is not possible to relieve discomfort, amnesia is desirable . Nonparalyzed patients should be sedate but sufficiently awake to communicate their needs to nurses and physicians; sedation to uncon sciousness is mandated during paralysis. The art of pain control is difficult at best in this setting, where patient comfort must be balanced against the numerous adverse drug effects. Unfortunately, concerns over safety often cause nurses and physicians to err on the side of insufficient relief of patient discomfort. The understandable reluctance to sedate patients who are not receiving mechanical ventilation for fear of producing respiratory depression often leaves nonintubated patients anxious and in pain. In addition to the discomfort itself, unrelieved pain can cause splinting that leads to atelectasis.
Pain also discourages activity, promoting deep venous throm bosis and deconditioning.
While every effort should be made to maximize patient comfort, excessive sedative or analgesic use can produce numerous complications. Excessive seda tion causes hypotension, gastrointestinal hypomotility, and masks the occurrence of intercurrent illnesses. Pharmaco logic obtundation also reduces tidal volume, vital capacity, minute ventilation, and inhibits forceful coughing.
CORRECTABLE FACTORS CAUSING AGITATION
Agitation or lack of patient cooperation should not be regarded as a â€oe¿ sedative deficiency.â€•Before sedating or sedating and paralyzing uncomfortable patients, especially those being mechanically ventilated, it is critical that cor rectable problems be excluded. Endotracheal tube patency and position should be confirmed, and ventilator set-up and connections should be double checked. Hypoxemia, pneu mothorax, and distention ofthe stomach and bladder should be excluded. Shortly after intubation, patients often have difficulty interfacing with the ventilator and comfort may be enhanced by varying ventilatory mode, tidal volume, flow rate, and trigger sensitivity. The administration of 5 to 10 ml of 2 percent lidocaine into the endotracheal tube after intubation can reduce tracheal irritation and patient discom fort early after intubation.
ChooSING PHARMACOLOGIC AGENTS
The choice of a sedative or paralytic drug, dosage, and route of administration should be made rationally based upon pharmacologic properties of the drug and individual patient requirements. Three common problems occur with the use of sedative, analgesic, and paralytic drugs in the ICU. Probablythe mostcommonerror is inadequate useof analgesics, particularly administration of insufficient doses ofanalgesics on too infrequent a schedule. The second most common problem is the use of ultra-short-acting agents when long-term (days) sedation, analgesia, or paralysis is the goal. Use of short-acting agents theoretically offers the flexibility of rapid interruption of drug effect, but rapid reversal is rarely necessary in the ICU, and undersedation is often the result of using short-acting drugs. When drug effects must be reversed, naloxone promptly interrupts narcotic effects, and flumazenil@'Â°can counteract benzodi azepine effects. The use of short-acting drugs for long-term indications is also costly and even short-acting compounds and their metabolites can accumulate in the critically ill when used for hours or days, negating their â€oe¿ short-actingâ€• advantages. @ The third and unforgivable error is paralyzing awake patients.'7'9 This practice is never acceptable and must be avoided at all cost.
Narcotics

ANALGESICS
Narcotics are the mainstay of ICU analgesia. There is a vast experience with these potent pain relievers, and gen erally, the actions of these drugs are predictable and rapidly reversible. Operating room experience has taught that the opiods are excellent analgesics but poor amnestic agents, and use of narcotics alone results in an unacceptably high incidence ofrecall in paralyzed patients.@2'When customary doses are used alone, narcotics cause few hemodynamic or respiratory effects. Although low narcotic doses are sufficient for analgesia, large doses (up to ten times the usual analgesic dose) may be necessary to produce surgical grade anesthesia, and at these â€oe¿ anestheticâ€• doses, narcotics are more likely to produce adverse effects.@ The addition of neuromuscular blockers, barbiturates, benzodiazepines, or phenothiazines is more likely to result in hypotension.
Opioid-induced constant intravenous infusion are usually adequate for relief of moderate pain in the average sized adult. In the ICU , the intravenous administration rate ofmorphine should probably not exceed 10 mg/mm to minimize the risk of hypotension. Although morphine is an excellent analgesic, high doses or combined use with a benzodiazepine is required to produce unconsciousness mandated by the use of paralytic agents. Low doses of morphine rarely produce hypotension; how ever, high morphine doses or combined use with l)enzodi azepines is much more likely to result in significant blood pressure reductions.@'@ A small fraction of morphine is directly excreted by the kidney without metabolism, but the majority of a dose of morphine is hepatically metabolized before renal excretion of the inetabolites!@ Therefore, the action ofmorphine is prolonged in renal and hepatic failure.
Meperidine offers no substantial advantage over @nor phine. Meperidine's atropine-like structure and vagolytic and histamine-releasing tendencies often cause tachycardia and hypotension. Meperidine's major metabolite, norme peridine, is active, accumulates in patients with renal failure, and has been associated with seizure activity when present in high concentrations. Meperidine is also a greater myocar dial depressant than other narcotics.
Fentanyl is a very potent (50 to 1(X) X the potency of Fentanyl and its metabolites accumulate to an even greater degree in the presence of hepatic and renal dysfunction.
Profound chest wall rigidity may develop after any opiate administration, however, fentanyl is the most common offender. Chest wall rigidity may be so severe that sponta neous or assisted ventilation is impossible unless neuromus cular paralysis intubation and mechanical ventilation are undertaken. Fortunately, this side-effect is rare and is seen most commonly when large intravenous doses are given rapidly to elderly patients. High doses of fentanyl may also cause seizures. The biggest disadvantage of fentanyl is its high cost relative to morphine.
The recent availability of a transdermal formulation offers another potentially useful route to deliver up to 50 to 100 @i.g of fentanyl per hour. Unfortunately, the skin slows diffusion offentanyl into the circulation producing a long lag time (hours) between patch application and effective anal gesia that usually requires interim parenteral analgesic is also a promising therapy to reduce narcotic requirements in postoperative or trauma pafients.@ The narcotic antagonist, naloxone, promptly reverses the effects of excessive narcotic sedation. Intravenous doses of 0.4 to 2 mg are usually sufficientfor at least transient narcotic reversal. Naloxone's duration ofaction is not as long as many commonly used narcotics, necessitating close ob servation and occasionally repeated naloxone administration to prevent recurrence of sedation.
Morphine is an inexpensive drug with a relatively rapid onset of action and 1 to 3 h half-life. Morphine's lower lipid solubility than the synthetic opiates produces a slower onset of action. The most common mistake made in the use of morphine is to administer too little too infrequently. Based upon morphine's half-life, the drug must be given every 2 to 3 h. Intermittent dosesof 5 to 10 mg intramuscularly or 
Nonstemidiji Anti-inflammatory Agents
Nonsteroidal anti-inflammatory agents (NSAIDs) are of ten overlooked in the ICU because of their antiplatelet activity and reputation to cause bleeding and renal insuffi ciency. The NSAIDs are potent antipyretic analgesics espe cially effective for musculoskeletal pain. These simple inex pensive compounds (eg, aspirin, and ibuprofen) often suffice for pain relief alone hut are also synergistic with narcotics.
A major drawback to the use ofNSAIDs is that most of these agents are only available in oral formulations.
Only one nonsteroidal compound, ketorolac, is currently available in parenteral form, but ketorolac does not offer unique prop 
NEUROMUSCULAR PARALYI'IC AGENTS
A detailed account ofneuromuscular physiology is beyond the scope of this paper; however, recent excellent reviews are available on this topic.51@
Mechanism ofAction ofNeuromuscular Blockers
Normally, neural impulses reach the neuromuscular june tion causing calcium-mediated release of acetylcholine into the junctional space. Acetylcholine then binds to specific receptors on the muscle causing a sodium-potassium flux or depolarization.
Through In the ICU, paralytic agents are rarely needed when adequate sedation is employed. Paralysis must never be used without sedation adequate to produce unconsciousness and should be used for the shortest possible period of time. Four major indications exist for the use of neuromuscular blockers in the ICU @2 Muscle relaxation to facilitate endotracheal intubation is probably the most common indication, but extreme caution must be used. As a general rule, the more likely one believes paralysis is needed to accomplish intubation, the less likely it is that paralytic drugs should be used. For example, use of paralytics in obese patients, or those with spinal instability or head or neck trauma who are inherently difficult to intubate without paralysis can result in complete upper airway obstruction. When using paralytic drugs for Intubation, provisions to surgically secure the airway must always be made. to ++MinimalRenal atous states produce complex problems. By increasing the volume of distribution of neuromuscular blockers, edema makes initial paralysis more difficult to achieve. However, the large reservoir of drug that accumulates in edema fluid may lead to a prolonged recovery phase. Recent reports indicate that higher dosesofparalytic agents may be required after prolonged use in the ICU.@ Respiratory acidosis and metabolic alkalosis,@@'hypoka lemia, hyponatremia, hypocalcemia, and hypermagnesemia all potentiate the neuromuscular blockade.@ Patients with â€oe¿ deinnervation hypersensitivity' caused by neuromuscular diseases such as myasthenia gravis and Guillain-Barre syn drome, are particularly sensitive to depolarizing paralytic agents.@ Use of beta blockers, calcium channel blockers, cyclosporine, aminoglycosides, tetracycline, clindamycin, and the antiarrhythmics, procanamide and quinidine, also potentiate neuromuscular blockers.'@'Â°@ The activity of par alytic agents will also be prolonged in hypothermic patients.
Histamine release is a feature of four commonly used nondepolarizing paralytics being most common with tubocurarine, followed by metocurine, atracurium, and mivacurium.'Â°@â€•M' Although histamine release can cause hypotension and bronchospasm, histamine's effects can be minimized by slow drug administration and by pretreatment with H, and H2 blockers.
Depolarizing Neuromuscular Blockers
Currently, succinylcholine is the only depolarizing agent in use. Succinylcholine has a very rapid onset of action (seconds) because of its low lipid solubility and a brief duration (< 10 mm) because of rapid degradation by plasma cholinesterase. Most of an administered bolus dose of succinylcholine never reaches the neuromuscular junction as it is rapidly degraded in the blood by pseudocholinester ase. The depolarization induced by succinylcholine causes fasciculations in skeletal muscle but does not effect smooth muscle â€˜¿ Â°@ Rapid intravenous injection of succinylcho line (1 mg/kg) is preferred by many for intubation because of its rapid onset, brief duration, and absence of smooth muscle action. Hypothermia decreases the metabolism of succinylcholine resulting in prolonged paralysis.
Succinylcholine is not without side effects. Most adult patients develop a sympathomimetic response, however, histamine release and resultant hypotension may occur especially when succinylcholine is combined with barbitu rates. Succinylcholine is not ideally suited for repeated injection nor for prolonged constant infusion because when given in this manner, it causes vagal stimulation and brady carcha, an effect more prominent in children. If more than one dose ofsuccinylcholine is ever necessary,atropine should be given intravenously prior to the second dose. tRarely used because of potent vagolytic actions.
Nondepolarizing Neuromuscular Blockers
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The duration of action rangesfrom 20 to 30 mm for mivacurium to often more than an hour for pipecuronium, pancuronium, doxacurium,â€•@ metocurine, and tubocura rifle. Pancuronium is the least expensive of the long-acting nondepolarizing agents. Unfortunately, pancuronium, tu 
Complications ofParalytic Agents
Prolonged Paralysis: Pseudocholinesterase, also known as plasma cholinesterase, is a plasma enzyme that metabolizes acetylcholine and succinylcholine . Pseudocholinesterase normally metabolizes the vast majority of a succinylcholine dose long before it has an opportunity to reach the neuro muscularjunction. Genetic and acquired reductions in levels of this enzyme increase the duration of succinylcholine induced paralysis. Between 1 and 5 percent of patients are heterozygous for plasma cholinesterase resulting in an extension of the duration of succinylcholine-induced paral ysis by only several minutes in most cases. These will be tense minutes indeed ifintubation cannot be accomplished. Approximately 1 out of 2,500 to 3,000 persons has a homozygous deficiency for pseudocholinesterase, extending the duration ofthe paralysis ofsuccinylcholine from minutes to6to8h.
Since the goal oftherapy in the ICU is usually to produce paralysis lasting hours (unlike the goal in the surgical suite), prolongation of succinylcholine-induced paralysis is usually of little consequence unless intubation cannot be accom 
Reversal ofNeuromuscular Blockade
Even when used in the operating suite, controversy surrounds the need for reversal of neuromuscular paralysis, and in the ICU, it is rarely necessary. Reversing agents act by raisingacetylcholinelevelsin the neuromuscular june tion. Therefore, reversing agents are not effective for block ade resulting from depolarizing agents (succinylcholine) or from profound (ion channel) blockade due to nondepolarizing blockers. Neostigmine, pyridostigmine, and edrophonium are the three agents available to reverse mild depolarizing blockade. Neostigmine isthemostcommonly usedreversing agent in the ICU, but only one in four ICU physicians commonly uses paralytic reversers. The major toxic effect of these drugs is muscarinic stimulation resulting in severe bradycardia and salivation. 
